TScan Therapeutics, Inc. (TCRX): Depreciation & Amortization
$2.90M
Year ended 2025-12-31
-17.2%
3-year compound annual growth
+19.3%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.90M | -29.3% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $4.10M | -24.1% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $5.40M | +5.9% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $5.10M | +54.5% | 2024-03-06, From 2022-01-01 |
| 2021-12-31 | $3.30M | +175.0% | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | $1.20M | n/a | 2022-03-09, From 2020-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $2.90M | -29.3% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $58.6K | -27.9% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $3.65M | -7.2% |
| Curis Inc (CRIS) | 2025-12-31 | $169.0K | -16.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $699.0K | +19.1% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $12.90M | -32.0% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $2.99M | +9.8% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $287.0K | +394.8% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $73.0K | -1.4% |
Compare TCRX, ACOG, CRBU, CRIS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗